Sotorasib (AMG 510) is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. In December 2019, it was approved to begin Phase 2 clinical trials.

Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocarcinoma patients and 5% of colorectal cancer patients, and sotorasib is the first drug candidate to target this mutation, there have been high expectations for the drug.The Food and Drug Administration has granted a fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma with the G12C KRAS mutation.

Pic